E
Entera Bio Ltd.
ENTXCIK 0001638097NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)L3ILFY ends Dec 31
Period
FY 2025
Revenue
$42.0K
Net Income
$-11.44M
Total Assets
$15.99M
Equity
$13.10M
Shares Out
46.62M
Op. Cash Flow
$-7.37M
Business
Entera Bio Ltd. is a clinical-stage company developing first-in-class oral tablet formats of peptide and protein replacement therapies for underserved chronic medical conditions. It offers its proprietary N-Tab™ oral delivery platform and product candidates, including EB613 (oral PTH(1-34) for osteoporosis), EB612 (oral PTH(1-34) for hypoparathyroidism), and oral GLP-2 and OXM (GLP-1/Glucagon) programs in collaboration with OPKO. Key business activities comprise research and development, clinical development, intellectual property management and strategic collaborations. The company conducts global clinical trials, pursues regulatory approvals in the U.S., EU, Israel and other jurisdictions, and plans commercialization through regional and global partners and contract manufacturing channels.
Summary from filing dated 2025-03-28
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| REVENUES | 42,000 | 181,000 | 0 | 134,000 | 571,000 | |
| COST OF REVENUES | 42,000 | 172,000 | 0 | 101,000 | 373,000 | |
| GROSS PROFIT | 0 | 9,000 | 0 | 33,000 | 198,000 | |
| Research and development, net | 6 | 4 | 5 | 6 | 7 | |
| General and administrative | 6 | 5 | 4 | 7 | 6 | |
| TOTAL OPERATING EXPENSES | 12 | 10 | 9 | 13 | 12 | |
| OPERATING LOSS | 12 | 10 | 9 | 13 | 12 | |
| FINANCIAL INCOME, NET | −90,000 | −58,000 | −31,000 | −83,000 | 29,000 | |
| LOSS BEFORE INCOME TAX | 11 | 10 | 9 | 13 | 12 | |
| INCOME TAX EXPENSES | 0 | 14,000 | 29,000 | 137,000 | −59,000 | |
| NET LOSS | 11 | 10 | 9 | 13 | 12 | |
| LOSS PER SHARE BASIC | 0.25 | 0.25 | 0.31 | 0.45 | 0.47 | |
| LOSS PER SHARE DILUTED | 0.25 | 0.25 | 0.31 | 0.45 | 0.47 | |
| WEIGHTED-AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC LOSS PER SHARE | 46 | 38 | 29 | 29 | 26 | |
| WEIGHTED-AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF DILUTED LOSS PER SHARE | 46 | 38 | 29 | 29 | 26 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 7 | 9 | 11 | 12 | 25 | |
| Accounts receivable | 0 | 126,000 | 0 | 246,000 | 183,000 | |
| Restricted cash | 8 | 0 | — | — | — | |
| Other current assets | 415,000 | 186,000 | 238,000 | 294,000 | 254,000 | |
| TOTAL CURRENT ASSETS | 15 | 9 | 11 | 13 | 25 | |
| Property and equipment, net | 134,000 | 57,000 | 100,000 | 139,000 | 156,000 | |
| Operating lease right-of-use assets | 465,000 | 275,000 | 388,000 | 90,000 | 239,000 | |
| Restricted deposit | 90,000 | 80,000 | 0 | — | — | |
| Funds in respect of employee rights upon retirement | 6,000 | 6,000 | 6,000 | 6,000 | 46,000 | |
| TOTAL NON-CURRENT ASSETS | 695,000 | 418,000 | 508,000 | 278,000 | 658,000 | |
| TOTAL ASSETS | 16 | 9 | 12 | 13 | 26 | |
| Accounts payable | 448,000 | 132,000 | 83,000 | 17,000 | 166,000 | |
| Accrued expenses and other payables | 2 | 874,000 | 874,000 | 1 | 3 | |
| Current maturities of operating lease | 230,000 | 170,000 | 134,000 | 91,000 | 179,000 | |
| TOTAL CURRENT LIABILITIES | 2 | 1 | 1 | 1 | 3 | |
| Operating lease liabilities | 260,000 | 102,000 | 256,000 | 0 | 123,000 | |
| Other long-term liability | 393,000 | 0 | — | — | — | |
| Liability for employee rights upon retirement | 36,000 | 32,000 | 32,000 | 32,000 | 138,000 | |
| TOTAL NON-CURRENT LIABILITIES | 689,000 | 134,000 | 288,000 | 32,000 | 261,000 | |
| TOTAL LIABILITIES | 3 | 1 | 1 | 1 | 3 | |
| COMMITMENTS AND CONTINGENCIES | — | — | — | — | — | |
| Ordinary Shares, NIS 0.0000769 par value: Authorized - as of December 31, 2025 and December 31, 2024, 140,010,000 shares; issued and outstanding as of December 31, 2025, and December 31, 2024, 46,178,630 and 38,837,220 shares, respectively | 1,000 | 1,000 | 1,000 | — | — | |
| Additional paid-in capital | 138 | 122 | 115 | 107 | 105 | |
| Accumulated other comprehensive income | 41,000 | 41,000 | 41,000 | 41,000 | 41,000 | |
| Accumulated deficit | −125 | −114 | −104 | −95 | −82 | |
| TOTAL SHAREHOLDERS' EQUITY | 13 | 8 | 10 | 12 | 23 | |
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | 16 | 9 | 12 | 13 | 26 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation | 30,000 | 46,000 | 56,000 | 64,000 | 53,000 | |
| Deferred income taxes | 0 | 14,000 | 29,000 | 174,000 | −217,000 | |
| Share-based compensation | 3 | 3 | 2 | 2 | 2 | |
| Finance income, net | 32,000 | −5,000 | — | — | — | |
| Decrease (increase) in accounts receivable | 126,000 | −126,000 | 246,000 | −63,000 | 72,000 | |
| Increase in other current assets | −229,000 | −14,000 | 56,000 | −40,000 | 7,000 | |
| Increase in accounts payable | 316,000 | 49,000 | 66,000 | −149,000 | 2,000 | |
| Increase in accrued expenses and other payables and other long-term liability | 1 | 203,000 | −563,000 | −2 | 1 | |
| Net cash used in operating activities | −7 | −7 | −7 | −12 | −9 | |
| Purchase of property and equipment | −107,000 | −3,000 | −17,000 | −47,000 | −17,000 | |
| Net cash used in investing activities | −107,000 | −3,000 | −17,000 | −102,000 | −17,000 | |
| Proceeds from ordinary issuance of shares through ATM programs | 6 | 4 | 5,000 | 0 | 22 | |
| Issuance of ordinary shares, under collaboration agreement | 7 | 0 | — | — | — | |
| Issuance costs | −262,000 | −323,000 | −580,000 | — | — | |
| Exercise of warrants into ordinary shares | 508,000 | 90,000 | 0 | — | — | |
| Exercise of options into ordinary shares | 20,000 | 749,000 | 0 | 13,000 | — | |
| Net cash provided by financing activities | 14 | 4 | 6 | 13,000 | 25 | |
| EFFECT OF EXCHANGE RATE CHANGE ON CASH AND CASH EQUIVALENTS | 36,000 | 0 | — | — | — | |
| INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED DEPOSITS | 6 | −2 | −1 | −13 | 16 | |
| Interest received | 180,000 | 68,000 | 18,000 | 0 | — | |
| Operating lease right of use assets obtained in exchange for operating lease liabilities | 386,000 | 32,000 | 449,000 | 0 | 31,000 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro